Clinical Trial Update: A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A study update for CM313 in relapsed or refractory multiple myeloma spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CM313

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN